Skip to main content

Liquid Biopsy Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis

Key Prominent Players Covered in the Liquid Biopsy Market are Biocept, Inc., MDxHealth, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Bio-Rad Laboratories, Inc., ExoDx.

Pune, India, March 10, 2022 (GLOBE NEWSWIRE) — The global liquid biopsy market size is set to experience dynamic growth in the forthcoming years owing to the increasing prevalence of different types of cancers across the world, finds Fortune Business Insights™ in its report, titled “Liquid Biopsy Market, 2021-2028”.

In recent years, there has been an increasing prevalence of various types of cancers such as lung cancer, stomach cancer, and others among the majority of world population, which has resulted in the rising importance for the medical procedures such as liquid biopsy that proves useful in finding a variety of information about cancer diseases with the use of blood samples. Thus, this is a crucial factor responsible for the growth of this market.

Industry Development:

November 2019: Biocept, Inc. announced the commercial availability of its Target Selector pan-TRK assay, a liquid biopsy test to detect TRK biomarkers in the blood of patients diagnosed with cancer.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/liquid-biopsy-market-102506


Market Growth Drivers:

There have been an increasing research and development activities in liquid biopsy in order to ease the procedure of the treatment of cancer diseases. This is a major factor responsible for the growth of this market.

  • Introduction of Technologically Advanced Systems to Propel Liquid Biopsy Market Growth
  • Extensive Distribution Network, Strong Portfolio, and Stout Brand Presence to Boost the Market
  • Rapid Shift towards Latest Technology in Developed and Emerging Countries
  • Launch of Innovative and Advanced Products is Propelling the Growth of the Market
  • Clinical Efficiency of New Products to Boost its Adoption during 2021-2028
  • Higher Demand in COVID-19 Pandemic to Propel Liquid Biopsy Market Growth
  • Product Innovations and Regional Expansions to Augment Market Growth
  • Growing Research & Development Investments and Increasing New Product approvals to Drive Market Growth
  • Robust Product Offerings by Key Players to Propel Industry Growth
  • Strategic Partnerships Coupled with Strong Brand Presence to Foster Company Growth

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506


Market Segmentation:

On the basis of product, this market is categorized into kits and consumables, instruments, and services. Based on end-user, the market is divided into hospitals and physician laboratories, specialty clinics, academic and research centers, and others. In terms of geography, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Regional Insights:

  • North America region is anticipated to witness substantial growth in the liquid biopsy market share on account of the increasing application of liquid biopsy and rising research and development activities in liquid biopsy in this region.
  • Europe is projected to grow at a decent pace in this market owing to the increasing prevalence of cancer disease and the rising awareness about liquid biopsy among the people in this region.

Quick Buy Liquid Biopsy Market

https://www.fortunebusinessinsights.com/checkout-page/102506


List of Key Players Covered in the Liquid Biopsy Market Report:

  • Biocept, Inc.
  • MDxHealth
  • F. Hoffmann-La Roche Ltd
  • Genomic Health, Inc.
  • Bio-Rad Laboratories, Inc.
  • ExoDx.

What Fortune Business Insights Provides in Liquid Biopsy Market?

  1. CONSULTING SERVICES:

Our counselling administrations are committed to offer noteworthy bits of knowledge, assisting clients with focusing on gainful open doors. Regardless of whether you are a carefully prepared player or hoping to investigate possibilities for speculation.

  1. SYNDICATED MARKET RESEARCH:

Forward-thinking data on winning business sector patterns and difficulties can deliver an organization solid in the midst of rivalry. Fortune Business Insights has a noteworthy store of off-the-rack partnered market studies across different enterprises.

  1. COMPETITIVE INTELLIGENCE:

Serious insight is a straightforward method we follow to help our statistical surveying. We offer significant bits of knowledge about a designated commercial center and planned purchasers to assist companies with effectively sending off items or decide their advertising effort.

  1. EMERGING TECHNOLOGIES:

With the advanced change in progress and the approach of cloud, there is a squeezing need among organizations to acquire pace with arising innovation patterns. Because of this, the interest for proper data on arising advances has soar.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/liquid-biopsy-market-102506


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.